What is claimed is:

1. An isolated antigen-binding protein, comprising HCDR3, HCDR2 and HCDR1, wherein said HCDR3 comprises an amino acid sequence as set forth in SEQ ID NO: 67, wherein said HCDR2 comprises an amino acid sequence as set forth in SEQ ID NO: 68 or SEQ ID NO: 11, and wherein said HCDR1 comprises an amino acid sequence as set forth in any one of SEQ ID NO: 2, SEQ ID NO: 10, and SEQ ID NO: 16.
2. The isolated antigen-binding protein of claim 1, wherein said HCDR3 comprises an amino acid sequence as set forth in any one of SEQ ID NO: 4, SEQ ID NO: 12, and SEQ ID NO: 18, wherein said HCDR2 comprises an amino acid sequence as set forth in SEQ ID NO: 3 or SEQ ID NO: 17, and wherein said HCDR1 comprises an amino acid sequence as set forth in any one of SEQ ID NO: 2, SEQ ID NO: 10, and SEQ ID NO: 16.
3. The isolated antigen-binding protein of claim 1, comprising a VH, wherein said VH comprises an amino acid sequence as set forth in SEQ ID NO: 78.
4. The isolated antigen-binding protein of claim 3, wherein said VH comprises an amino acid sequence as set forth in any one of SEQ ID NO: 1, SEQ ID NO: 9, SEQ ID NO: 15, and SEQ ID NO: 19.
5. The isolated antigen-binding protein of claim 1, comprising LCDR3, LCDR2 and LCDR1, wherein said LCDR3 comprises an amino acid sequence as set forth in SEQ ID NO: 69, wherein said LCDR2 comprises an amino acid sequence as set forth in SEQ ID NO: 70, and wherein said LCDR1 comprises an amino acid sequence as set forth in SEQ ID NO: 71.
6. The isolated antigen-binding protein of claim 5, wherein said LCDR3 comprises an amino acid sequence as set forth in any one of SEQ ID NO: 8, SEQ ID NO: 14, SEQ ID NO: 23, and SEQ ID NO: 25, wherein said LCDR2 comprises an amino acid sequence as set forth in SEQ ID NO: 7 or SEQ ID NO: 22, and wherein said LCDR1 comprises an amino acid sequence as set forth in SEQ ID NO: 6 or SEQ ID NO: 21.

7. The isolated antigen-binding protein of claim 1, comprising a VL, wherein said VL comprises an amino acid sequence as set forth in SEQ ID NO: 79.
8. The isolated antigen-binding protein of claim 7, wherein said VL comprises an amino acid sequence as set forth in any one of SEQ ID NO: 5, SEQ ID NO: 13, SEQ ID NO: 20, and SEQ ID NO: 24.
9. The isolated antigen-binding protein of claim 1, comprising any set of amino acid sequences selected from the group consisting of:
    1) said VH comprising the amino acid sequence as set forth in SEQ ID NO: 1 and said VL comprising the amino acid sequence as set forth in SEQ ID NO: 5;
    2) said VH comprising the amino acid sequence as set forth in SEQ ID NO: 15 and said VL comprising the amino acid sequence as set forth in SEQ ID NO: 5;
    3) said VH comprising the amino acid sequence as set forth in SEQ ID NO: 9 and said VL comprising the amino acid sequence as set forth in SEQ ID NO: 13;
    4) said VH comprising the amino acid sequence as set forth in SEQ ID NO: 19 and said VL comprising the amino acid sequence as set forth in SEQ ID NO: 20; or
    5) said VH comprising the amino acid sequence as set forth in SEQ ID NO: 19 and said VL comprising the amino acid sequence as set forth in SEQ ID NO: 24.
10. The isolated antigen-binding protein of claim 1, comprising an antibody heavy chain constant region.
11. The isolated antigen-binding protein of claim 10, wherein said antibody heavy chain constant region is derived from a human IgG1 heavy chain constant region.
12. The isolated antigen-binding protein of claim 1, comprising an antibody light chain constant region.
13. The isolated antigen-binding protein of claim 12, wherein said antibody light chain constant region is derived from a human Igκ constant region.
14. A chimeric antigen receptor, comprising a targeting moiety, wherein said targeting moiety comprises the antigen-binding protein of any one of claims 1-13.
15. The chimeric antigen receptor of claim 14, comprising a costimulatory domain, an intracellular signaling domain, a transmembrane region, a hinge region between the

targeting moiety and the transmembrane region, and a signal peptide; wherein said costimulatory domain comprises a costimulatory domain derived from one or more proteins selected from the group consisting of: CD28, 4-1BB, CD27, CD2, CD7, CD8, OX40, CD226, DR3, SLAM, CDS, ICAM-1, NKG2D, NKG2C, B7-H3, 2B4, FcεRIγ, BTLA, GITR, HVEM, DAP10, DAP12, CD30, CD40, CD40L, TIM1, PD-1, LFA-1, LIGHT, JAML, CD244, CD100, ICOS, a ligand of CD83, CD40, and MyD88, wherein said intracellular signaling domain comprising an intracellular signaling domain derived from one or more proteins selected from the group consisting of: CD3ζ, CD3δ, CD3γ, CD3ε, CD79a, CD79b, FcεRIγ, FcεRIβ, FcγRIIa, bovine leukemia virus gp30, Epstein-Barr virus (EBV) LMP2A, simian immunodeficiency virus PBj14Nef, Kaposi's Sarcoma Associated-Herpesvirus (HSKV), DAP10, DAP-12, and a domain containing at least one ITAM, wherein said transmembrane region comprises a transmembrane domain derived from one or more proteins selected from the group consisting of: CD8, CD28, 4-1BB, CD4, CD27, CD7, PD-1, TRAC, TRBC, CD3ε, CD3ζ, CTLA-4, LAG-3, CD5, ICOS, OX40, NKG2D, 2B4, CD244, FcεRIγ, BTLA, CD30, GITR, HVEM, DAP10, CD2, NKG2C, LIGHT, DAP12, CD40L, TIM1, CD226, DR3, CD45, CD80, CD86, CD9, CD16, CD22, CD33, CD37, CD64, CD134, CD137, CD154, and SLAM, wherein said hinge region comprises a hinge region derived from one or more proteins selected from the group consisting of: CD28, IgG1, IgG4, IgD, 4-1BB, CD4, CD27, CD7, CD8, PD-1, ICOS, OX40, NKG2D, NKG2C, FcεRIγ, BTLA, GITR, DAP10, CD40L, TIM1, CD226, SLAM, CD30, and LIGHT.

16. The chimeric antigen receptor of claim 15, wherein said costimulatory domain is an intracellular costimulatory signaling region derived from 4-1BB comprising an amino acid sequence as set forth in SEQ ID NO: 85, wherein said intracellular signaling domain is a signaling domain derived from CD3ζ comprising an amino acid sequence as set forth in SEQ ID NO: 86, wherein said transmembrane region is a transmembrane region derived from CD8 comprising an amino acid sequence as set forth in SEQ ID NO: 84, wherein said hinge region is a hinge region derived

from CD8 comprising an amino acid sequence as set forth in SEQ ID NO: 83, wherein said signal peptide is a signal peptide derived from the CD8 protein comprising an amino acid sequence as set forth in SEQ ID NO: 88.

17. The chimeric antigen receptor of claim 14, further comprising a low-density lipoprotein receptor-related protein or a fragment thereof.
18. The chimeric antigen receptor of claim 17, wherein said low-density lipoprotein receptor-related protein or the fragment thereof comprises one or more groups selected from: low-density lipoprotein receptor-related proteins 1-12 and functional fragments thereof.
19. The chimeric antigen receptor of claim 17, wherein said low-density lipoprotein receptor-related protein or the fragment thereof comprises an amino acid sequence as set forth in SEQ ID NO: 91.
20. A polypeptide molecule comprising the isolated antigen-binding protein of any one of claims 1-13 or the chimeric antigen receptor of any one of claims 14-19.
21. An immunoconjugate, comprising the isolated antigen-binding protein of any one of claims 1-13.
22. One or more isolated nucleic acid molecules, encoding the isolated antigen-binding protein of any one of claims 1-13, the chimeric antigen receptor of any one of claims 14-19 or the polypeptide molecule of claim 20.
23. A cell, comprising the isolated antigen-binding protein of any one of claims 1-13, the chimeric antigen receptor of any one of claims 14-19, the polypeptide molecule of claim 20, or the nucleic acid molecule of claims 22.
24. A pharmaceutical composition, comprising the isolated antigen-binding protein of any one of claims 1-13, the chimeric antigen receptor of any one of claims 14-19, the polypeptide molecule of claim 20, the immunoconjugate of claim 21, the nucleic acid molecule of claim 22, and/or the cell of claim 23, and optionally a pharmaceutically acceptable carrier.
25. Use of an isolated antigen-binding protein of any one of claims 1-13, a chimeric antigen receptor of any one of claims 14-19, a polypeptide molecule of claim 20,

an immunoconjugate of claim 21, a nucleic acid molecule of claim 22, a cell of claim 23, and/or a pharmaceutical composition of claim 24, in the manufacture of a medicament for the prevention, alleviation and/or treatment of a disease and/or a disorder.

26. The use of claim 25, wherein said disease and/or the disorder comprises cancers.
27. The use of claim 26, wherein said cancers comprise solid tumors and/or hematomas.
28. The use of claim 26, wherein said cancers comprise gastric cancer and/or colon cancer.